Neuroendocrine tumors of the vagina

The paper covers the most important topographic-anatomic and histological characteristics of the vagina, gives general information on the epidemiology of primary vaginal cancer (VC), on the rules of its staging, describes the frequently encountered morphological types of this tumor, and indicates the properties and features of the course of neuroendocrine tumors (NETs), including the most common manifestations of carcinoid syndrome and the symptoms of tumor hypersecretion of a number of biologically active substances. It also indicates the most common sites of NETs, the rules of their classification according to the grade and mitotic activity of tumor cells, as well as major methods for biochemical and radiological diagnosis. The immunohistochemical NET markers that can diagnose VC, their physiological role, sensitivity, and specificity, as well as the possibility of determining them in the body’s biological environments in order to increase physicians’ awareness are described in detail and the main aspects of tumor immunohistochemical staining are denoted. The role of circulating tumor cells as a promising method to specify the extent of NETs is defined. The paper gives epidemiological information on the development of vaginal NET and summarizes the available data by their clinical course and treatment results. It provides current guidelines on the required treatment volume and specifies the role of surgical intervention and the necessary volume if the intervention is expedient. It sets forth the up-to-date guidelines for chemotherapy for small cell tumors, as well as VC, which includes the specific features of managing patients with tumor recurrences depending on the time of their development. 

1. Berek J.S., Hacker N.F. Berek and Hecker’s Gynecologic Oncology. 6th еd. Wolters Kluwer, 2015. Рp. 608–9.

2. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. T.V. DeVita Jr, T.S. Lawrence, S.A. Rosenberg (eds.). 10th ed. Lippincott Williams & Wilkins, 2015. Pp. 1013–8.

3. Cunningham F., Leveno K., Bloom S. et al. Williams Obstetrics. 24th ed. McGraw-Hill Professional, 2009. Pp. 20–1.

4. Кузнецов С.Л., Мушкамбаров Н.Н. Гистология, цитология и эмбриология. М., 2007. C. 557. [Kuznetsov S.L., Mushkambarov N.N. Histology, cytology and embryology. Мoscow, 2007. P. 557. (In Russ.)].

5. Mescher A.L. Junqueira basic histology. 13th ed. McGrawHill, 2013. P. 518.

6. Gray’s Anatomy. The anatomical basis of clinical practice. 40th ed. S. Standring (ed.). Churchill Livingstone Elsevier, 2008. Pp. 2347–9.

7. World Health organization classification of tumours. Tumours of the breast and female genital organs. Lyon: IARC Press, 2003.

8. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. T.V. DeVita Jr, T.S. Lawrence, S.A. Rosenberg (eds.). 10th ed. Lippincott Williams & Wilkins, 2015. P. 2848.

9. Standring S. et al. Gray’s Anatomy. The anatomical basis of clinical practice. 40th ed. Churchill Livingstone Elsevier 2008. Pp. 112–3.

10. Нейроэндокринные опухоли: руководство для врачей. Пер. с англ. под ред. М. Кэплина, Л. Кволса. М.: Практическая медицина, 2011. С. 11; 17–19; 23; 37; 43; 54; 88; 100. [Neuroendocrine tumors: manual for physicians. Transl. from Enlgish. Ed. by М. Caplin, L. Kvols. Мoscow: Practical medicine, 2011. Pp. 11; 17–19; 23; 37; 43; 54; 88; 100. (In Russ.)].

11. Симоненко В.Б., Дулин П.А., Маканин М.А. Нейроэндокринные опухоли. М.: ГЭОТАР-Медиа, 2010. С. 6; 16. [Simonenko V.B., Dulin P.А., Маkanin М.А. Neuroendorcine tumors. Мoscow: GEOTARМеdia, 2010. Pp. 6; 16. (In Russ.)].

12. Gardner G.J., Reidy-Lagunes D., Gehrig P.A. Neuroendocrine tumors of the gynecologic tract: a society of gynecologic oncology (SGO) clinical document. Gynecol Oncol 2011;122(1): 190–8.

13. Surveillance, epidemiology, and end results (SEER), Program 2005 Public-use data (1973–2002). National Cancer Institute, DC-CPS, Surveillance Research Program, Cancer Statistics Branch. National Cancer Institute, Bethesda, MD. (Released April 2005, based on the November 2004 submission).

14. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. T.V. DeVita Jr, T.S. Lawrence, S.A. Rosenberg (eds.). 10th ed. Lippincott Williams & Wilkins, 2015. Pp. 3412–3.

15. National comprehensive cancer network. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors, v. 1.2015.

16. Klimstra D.S., Modlin I.R., Coppola D. et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39(6):707–12.

17. Coleman N.M., Smith-Zagone M.J., Tanyi J. et al. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am J Surg Pathol 2006;30(3):405–10.

18. Colleran K.M., Burge M.R., Crooks L.A., Dorin R.I. Small cell carcinoma of the vagina causing Cushing's syndrome by ectopic production and secretion of ACTH: a case report. Gynecol Oncol 1997;65(3):526–9.

19. DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. T.V. DeVita. Jr, T.S. Lawrence, S.A. Rosenberg (eds.). 10th ed. Lippincott Williams & Wilkins, 2015. P. 2448.

20. Bhalodia J.N., Kapapura D.V., Parekh M.N. Primary small cell neuroendocrine carcinoma of vagina: a rare case report. Pathol Res Int 2011;2011:306921.

21. Novak J., Escobedo-Morse A., Kelley K. et al. Nicotine effects on proliferation and the bombesin-like peptide autocrine system in human small cell lung carcinoma SHP77 cells in culture. Lung Cancer 2000;29: 1–10.

22. Berek J.S., Hacker N.F. Berek and Hecker’s Gynecologic Oncology. 6th ed. Wolters Kluwer, 2015. P. 789–91.

23. Konecki D.S., Benedum U.M., Gerdes H.H. Huttner W.B. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987;262:17026–30.

24. Дзеранова Л.К., Парамонов В.М., Пигарова Е.А. Место хромогранина А в современной диагностике нейроэндокринных опухолей. Фарматека 2010;15(209):44–8. [Dzeranova L.K., Paramonov V.М., Pigarova Е.А. Role of chromogranine А in the modern diagnosis of neuroendorine tumors. Pharmateca 2010;15(209):44–8. (In Russ.)].

25. Nikou G.C., Marinou K., Thomakos P. et al. Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumors. Pancreatology 2008;8:510–19.

26. Campana D., Nori F., Piscitelli L. et al. Chromogranin A: is it a usefuk marker of neuroendocrine tumors? J Clin Oncol 2007;25:967–73.

27. Bajetta E., Ferrari L., Martinetti A. et al. Chromogranin A, neuron specific enolase, carcinoembryonic sntigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86: 858–65.

28. Kalkner K.M., Janson E.T., Nilsson S. et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55(23 Suppl): 5801s–4s.

29. Алясова А.В. Онкомаркеры. Нижегородский медицинский журнал 2005;(2): 44–9. [Аlyasovа А.V. Оncomarkers. Nizhegorodskiy meditsynskiy zhurnal = Nizhny Novgorod Medical Journal 2005;(2):44–9. (In Russ.)].

30. Энциклопедия клинических лабораторных тестов. Под ред. Н.У. Тица. М.: Лабинформ, 1997. 942 с. [Encyclopedia of clinical laboratory tests. Ed. by N.U. Tits. Мoscow: Labinphorm, 1997. 942 p. (In Russ.)].

31. Wu A. Tietz clinical guide to laboratory tests. Saunders, 2006. Рp. 358–9.

32. Bharti A., Ma P.C., Salgia R. Biomarker discovery in lung cancer – promises and challenges of clinical proteomics. Mass Spectrum Rev 2007;26(3):451–66.

33. Wiedenmann B., Franke W.W. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38 000 characteristic of presynaptic vesicles Cell 1985;41(3): 1017–28.

34. Bouranis L., Sperrin M., Greystoke A. et al. The interaction between prognostic and pharmacodynamic biomarkers. Br J Cancer 2013;109(7):1782–5.

35. Khan M.S., Kirkwood A., Tsigani T. et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol 2013;31(3):365–72.

36. Berek J.S., Hacker N.F. Berek and Hecker’s gynecologic oncology. 6th ed. Wolters Kluwer, 2015. Pp. 790–3.

37. AJCC Cancer Staging Manual. 7th ed., Springer, 2011. P. 387.

38. National comprehensive cancer network. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, v. 2.2015.

39. Rossi A., Maione P., Palazzolo G. et al. New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008;9(5):271–9.

40. Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10(6):890–5.

41. Pignon J.P., Arriagada R., Ihde D.C. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327(23):1618–24.

42. Singh V., Singh H., Leong C. et al. Vaginal small cell carcinoma: case report and review of literature. N-Y Med J 2008.